Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ernexa Therapeutics Inc. (ERNA)

Ernexa Therapeutics posts fact sheet and investor presentation dated September 16, 2026

Neutral Impact 1 of 5 other Written later

Ernexa Therapeutics Inc. made a corporate fact sheet and an investor presentation available on September 16, 2026, attached as Exhibits 99.1 and 99.2 to this Form 8-K. The filing does not disclose financial results, guidance, or other new operating figures in its text, and the company said the materials will also be posted on its website on September 17, 2026.

Key points

  • Corporate fact sheet dated September 16, 2026 filed as Exhibit 99.1
  • Investor presentation dated September 2026 filed as Exhibit 99.2
  • Materials to be posted at investor.ernexatx.com on September 17, 2026
  • Information is furnished under Item 7.01, not filed, under the Exchange Act

The filing

CompanyErnexa Therapeutics Inc. (ERNA)
Form8-K, current report
Filed with the SECSep 16, 2026, 5:30 PM ET
Accession number0001493152-26-042963

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.